Literature DB >> 31419217

MicroRNA-1297 inhibits proliferation and promotes apoptosis in gastric cancer cells by downregulating CDC6 expression.

Xiangqian Zhang1,2, Min Zhang3, Qingqing Guo1, Xiaoyi Hu4, Zhenghao Zhao1, Lei Ni1, Liying Liu1, Xiaofei Wang1, Zhenzhen Wang1, Dongdong Tong1, Su'e Chang5, Youlong Cao6, Chen Huang1,7.   

Abstract

Gastric cancer (GC), one of the most common malignant tumors and the second most common leading cause of cancer-related death worldwide, is a biologically heterogeneous disease accompanied by various genetic and epigenetic alterations. However, the molecular mechanisms underlying this disease are complex and not completely understood. Increasing studies have shown that aberrant microRNA (miRNA) expression is associated with GC tumorigenesis and growth. MiR-1297 has been confirmed to be a cancer suppressor in diverse tumors in humans. However, to date, the function and mechanism of miR-1297 in GC have not been determined. Here, we found that the expression of miR-1297 was significantly reduced in GC tissues or GC cell lines compared with paracarcinoma normal tissue or normal cell lines. Exogenic overexpression of miR-1297 in GC cell lines can inhibit cell proliferation and colony formation and induce apoptosis, and inhibition of miR-1297 in GC cell lines can promote cell proliferation and colony formation, and reduce apoptosis in vitro. We further confirmed that miR-1297 acted as a tumor suppressor through targeting cell division control protein 6 (CDC6) in GC. Moreover, the inverse relationship between miR-1297 and CDC6 was verified in GC cell lines. Our results indicated that miR-1297 is a potent tumor suppressor in GC, and its antiproliferative and gene-regulatory effects are, in part, mediated through its downstream target gene, CDC6. These findings implied that miR-1297 might be used as a novel therapeutic target of GC.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31419217     DOI: 10.1097/CAD.0000000000000776

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  7 in total

Review 1.  Clinical crosstalk between microRNAs and gastric cancer (Review).

Authors:  Jing Ouyang; Zhizhong Xie; Xiaoyong Lei; Guotao Tang; Runliang Gan; Xiaoyan Yang
Journal:  Int J Oncol       Date:  2021-03-02       Impact factor: 5.650

2.  Mechanism of miR-98 inhibiting tumor proliferation and invasion by targeting IGF1R in diabetic patients combined with colon cancer.

Authors:  Shixiong Liu; Yun Zhou; Yongning Zhou; Jing Wang; Rui Ji
Journal:  Oncol Lett       Date:  2020-06-09       Impact factor: 2.967

3.  miR-874 inhibits gastric cancer cell proliferation by targeting SPAG9.

Authors:  Qin Hui Sun; Zong Xiu Yin; Zhi Li; Shu Bo Tian; Hong Chang Wang; Fang Xu Zhang; Le Ping Li; Chun Ning Zheng; Shuai Kong
Journal:  BMC Cancer       Date:  2020-06-05       Impact factor: 4.430

4.  LncRNA SNHG6 knockdown inhibits cisplatin resistance and progression of gastric cancer through miR-1297/BCL-2 axis.

Authors:  Jiazhan Mei; Guiju Liu; Ruijun Li; Peng Xiao; Dan Yang; Hua Bai; Yibin Hao
Journal:  Biosci Rep       Date:  2021-12-22       Impact factor: 3.840

5.  Retracted Article: LncRNA SNHG5 regulates the cell viability and apoptosis of glioma cells by the miR-1297/KPNA2 axis.

Authors:  Xueyuan Li; Qiankun Liu; Kang Wang; Wenzheng Luo; Tiansong Liang; Shanpeng Yuan; Yingwei Zhen; Dongming Yan
Journal:  RSC Adv       Date:  2020-01-08       Impact factor: 4.036

6.  Replication Stress: A Review of Novel Targets to Enhance Radiosensitivity-From Bench to Clinic.

Authors:  Yuewen Zhang; Lei Wu; Zhao Wang; Jinpeng Wang; Shrabasti Roychoudhury; Bartlomiej Tomasik; Gang Wu; Geng Wang; Xinrui Rao; Rui Zhou
Journal:  Front Oncol       Date:  2022-07-08       Impact factor: 5.738

7.  Increased CDC6 Expression Associates With Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma.

Authors:  Yao Yicong; Yi Wang; Wu Denglong; Hu Baoying
Journal:  Front Oncol       Date:  2021-05-24       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.